SHANGHAI, CHINA, August 16, 2017 – Antengene Corporation, a clinical stage biopharmaceutical company, announced today the completion of its Series A financing. The investment was led by Qiming Venture Partners, joined by Huagai Capital, Tigermed and TF Capital.
Antengene plans to use proceeds to advance clinical development of ATG-008 in Asian countries as well as to further expand product portfolio of both pipeline assets at clinical development stage and mature products.
Dr. Jay Mei, founder of Antengene Corporation commented on the successful completion of series A financing that “we are very pleased to receive support from four of the leading healthcare investors. The enthusiasm of investors speaks to the great opportunity presented by Antengene. We will continue to relentlessly build a healthcare platform and narrow gaps in medical care between Asian and Western countries.”
Antengene Corporation is a clinical-stage biopharmaceutical company focusing on introducing cutting-edge treatments, from mid-to-late stage development pipeline to mature brands, to China and other Asian markets by leveraging clinical development and regulatory expertise in Asian Pacific countries as well as knowledge and experience with local markets. Driven by a larger purpose, Antengene aims at growing into a market leader in the development of innovative therapies to address unmet medical needs globally in the long term.